Gordian Surgical

Market position

The company competes in the laparoscopic port closure segment against manual suturing and standalone closure devices, positioning the TroClose as the only system on the market that does not require pneumoperitoneum or additional visualization for closure. It is a Trendlines Group portfolio company and attracted strategic investment from B. Braun Melsungen AG, whose management cited the global laparoscopic market opportunity for an integrated closure/trocar device.

Integration of trocar access and automated port-site closure in a single device, needle-less anchor-based half-loop suturing intended to reduce tissue tension and post-operative pain, closure that does not require pneumoperitoneum or added visualization, reduced SKU count for inventory-constrained facilities, and reduced single-use waste versus separate cannula and closure products.

Technology

The TroClose 1200 combines a laparoscopic cannula/trocar with an anchor-based, needle-less closure mechanism. Sutures are deployed at the start of the procedure through a 180-degree deployment forming a half-loop knot system with absorbable anchoring tags, said to cut tissue tension by 75% relative to full-loop systems. Closure is referenced from the peritoneum via the obturator to avoid toggle motion, and the system operates without pneumoperitoneum or additional visualization at the time of closure.

Go-to-market

The company sells through distributors and direct commercial efforts, supported by physician demonstrations, product demos requested through its website, and visibility at surgical and industry congresses such as MEDICA, the German Association for the Study of Obesity annual conference, and live surgery demonstrations including at IRCAD Strasbourg. Physician testimonials from surgeons at institutions including the Cleveland Clinic, Montefiore Medical Center, the University of Texas McGovern Medical School and East Sussex Healthcare NHS Hospital are used in marketing.

Laparoscopic and robotic surgeons, and the hospitals and ambulatory surgery centers where they operate, including bariatric and general surgery units.

Geography

Headquarters in Misgav Business Park, Misgav, Israel, with a US subsidiary office in New Jersey. Product use and sales are reported across the United States, Europe, Israel and Latin America, with commercialization efforts also targeting Asia.

History

The company was established at the end of 2012 as a portfolio company of The Trendlines Group. It received CE Mark certification for the TroClose1200 in September 2016 and FDA clearance in December 2016, announced alongside a $2.25 million financing round led by B. Braun Melsungen AG. Human trials began in 2016, with 50 laparoscopic procedures completed in the clinical phase and the first seven post-marketing surveillance cases performed in Europe, including at IRCAD in Strasbourg, France and during a live broadcast surgery in Germany. By October 2019, when the company raised a further $3 million, it described itself as commercial-stage with more than 3,000 cases completed and sales in Europe and Latin and Central America. Company materials later cite use in over 4,000 patients across 150 hospitals. Leadership has changed since the 2016-2019 announcements, when Zvi Pe'er was CEO; the current team lists Eddie Shaw as CEO, Tahel Perets as COO, Eran Feldhay as Chairman and Nissim Geron as Chief Medical Director.

Risks & controversies

Clinical and performance claims, including the 0% port-site hernia rate and the 75% tissue-tension reduction, derive from company-cited studies and a feasibility study rather than independent verification in the available material. Adoption depends on displacing manual suturing and incumbent closure devices; the company noted in 2019 that it still needed additional distributors and had yet to penetrate the U.S. market.